OncoGenex, Isis report Phase II success

OncoGenex and collaborator Isis Pharmaceuticals say that in a Phase II trial, OGX-011, in combination with either docetaxel or mitoxantrone, was well-tolerated as a second-line treatment for patients with prostate cancer. In addition, the trials demonstrated ongoing survival rates better than results published with chemotherapy alone.

"These data show that the combination of OGX-011 with docetaxel or mitoxantrone may improve treatment outcomes in second-line prostate cancer," said Dr. Fred Saad, the primary investigator in the study. "The data also suggests that re-treatment with docetaxel when combined with OGX-011 may reverse chemotherapy resistance in second-line docetaxel re-treatment." The results were presented at the 2008 Genitourinary Cancers Symposium. Planning is underway for a Phase III study utilizing chemotherapy plus OGX-011 as second-line therapy in patients progressing after a first-line docetaxel regimen.

- see OncoGenex's release for more

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.